BRP emerges as a promising peptide for weight loss, activating appetite control pathways without triggering nausea, paving the way for safer obesity therapies.

(RTTNews) - OPKO Health (OPK) and Entera Bio have entered a collaboration and license agreement to develop the first oral dual agonist GLP-1/glucagon peptide for obesity, metabolic, and fibrotic ...